In a groundbreaking move, Unity and AMILI have joined forces to launch a synbiotic product, AMILI Metabolic Health, tailored to Asian gut microbiomes. This innovative collaboration aims to address metabolic health challenges prevalent among Asian populations. The product's formulation is based on extensive Asian gut microbiome data, including insights from Singapore's National University Hospital (NUH) and AMILI's Asian Microbiome Library. Dr. Jeremy Lim, co-founder and CEO of AMILI, emphasizes the importance of Asian-specific solutions, stating, "An Asian gut is not the same as a Western one." This initiative marks a significant step towards personalized healthcare, recognizing the unique dietary, lifestyle, and environmental factors that influence Asian gut microbiomes.
Unlocking the Potential of Asian Microbiomes
The development of AMILI Metabolic Health showcases a meticulous R&D process. By comparing microbiome data from healthy individuals and hospital patients, the team identified key differences in microbial composition and interactions. Dr. Lim explains their functional pathway approach, studying the microbes and their metabolites to create a tailored formulation. The product contains a blend of probiotic strains, prebiotics, postbiotics, and botanical extracts, each carefully selected for its metabolic health benefits. For instance, Lactobacillus rhamnosus targets fasting blood glucose and liver function, while Akkermansia improves insulin sensitivity and total cholesterol.
Addressing Metabolic Health Challenges in Asia
Metabolic health was chosen as the focus for this collaboration due to its significance as a health challenge in Asia. Dr. Lim highlights the unique BMI thresholds for obesity and overweight in Asians, recognized by the World Health Organization. This distinction underscores the need for Asian-specific solutions. Singapore, in particular, faces a rising prevalence of metabolic and fatty liver conditions, with diabetes, high blood pressure, and hyperlipidemia being common health concerns. Associate Professor Dan Yock Young from NUH emphasizes the role of the gut microbiome in regulating these conditions and the potential for collaborations like this to deepen our understanding and develop new approaches to support Asian metabolic health.
A Step Towards Personalized Healthcare
The launch of AMILI Metabolic Health represents a significant advancement in personalized healthcare for Asians. By leveraging Asian microbiome data and clinical insights from Singaporean patients, this product offers a tailored solution for metabolic health. Pauline Png, general manager at Unity, FairPrice Group, highlights the Asian-specificity of the formulation, stating that it is the first of its kind available across Unity. With the support of pharmacists, Unity aims to promote public understanding of microbiome supplements' benefits for metabolic health. This initiative not only addresses a critical health challenge but also demonstrates the potential for data-driven, personalized healthcare solutions tailored to specific populations.
